Samsung Bioepis Wins 'iF Design Award', One of the World's Top 3 Design Competitions

Product package design of Samsung Bioepis (Provided by Samsung Bioepis)

[Asia Economy Reporter Lee Chun-hee] Samsung Bioepis has won grand prizes in two categories at the globally prestigious design competition, the 'iF Design Award 2021.'

Samsung Bioepis announced on the 22nd that it won grand prizes in two categories by submitting biopharmaceutical package designs to the iF Design Award 2021.

The iF Design Award is a design competition organized by the German International Forum Design since 1953. Along with the American 'International Design Excellence Awards (IDEA)' and the German 'Red Dot Design Award,' it is considered one of the world's top three design awards.

Samsung Bioepis was selected as a winner in the Communication and Packaging categories at this year's iF Design Award, which consists of a total of nine categories. Previously, in August last year, Samsung Bioepis won a grand prize at the Red Dot Design Award, another of the world's top three design awards, and in November, it also won a grand prize at the domestic 'Good Design Award,' continuing its winning streak in both domestic and international design competitions.

Samsung Bioepis participated in this design contest under the theme of 'pure joy,' meaning to provide chronic disease patients with the enjoyment of a healthy life. Beyond the traditional message focused on treatment found in existing pharmaceutical packaging, they developed graphic motifs that can provide psychological stability, aiming to achieve a visual therapeutic effect by conveying the message of 'return to daily life.'

Kim Jae-woo, Executive Director (Head of Production Division) at Samsung Bioepis, said, "Samsung Bioepis's brand design is being recognized by the world's top institutions," adding, "We will continue to strive to provide patients with a better life through our products.

New product design by Samsung Bioepis applied to Adaloce (Humira biosimilar) (Provided by Samsung Bioepis)

Samsung Bioepis plans to first introduce the new product designs to domestic patients. The new designs will be sequentially applied not only to existing marketed products such as Etoloce (Enbrel biosimilar), Remaroce (Remicade biosimilar), and Sampenet (Herceptin biosimilar) but also to upcoming products like Adaloce (Humira biosimilar) and Onbevzi (Avastin biosimilar).

This content was produced with the assistance of AI translation services.